Procyon's TVT-Dox for tumors demonstrates positive preclinical results

By Lisa Kerner

Erie, Pa., Feb. 7 - Procyon Biopharma Inc. said preclinical results show its novel tumor vasculature targeting drug, TVT-Dox, functionally disrupts tumor vasculature.

Research has shown TVT-Dox to be a very potent anti-tumor agent with seven out of seven positive results in animal models and six out of six positive results with human tumor biopsies, according to a company news release.

Procyon said TVT-Dox shows a broad spectrum of anti tumor activity, destroys tumor vasculature and has a high safety/efficacy profile.

The company expects to file an Investigational New Drug application for TVT-Dox within the next 12 months.

A TVT-Dox short report entitled: "A novel dual-targeting drug for solid tumors and their vasculature" was presented by Dr. Jinzi Wu, vice-president, preclinical and basic research of Procyon, at the 2006 Miami Nature Biotechnology Symposium on Angiogenesis in Cancer on Monday.

The short report confirms the selective binding capability of TVT-Dox to endothelial cells in tumor blood vessels and its effective delivery of the cytotoxic agent (doxorubicin) to the tumor blood vessels and adjacent tumor cells, the release stated.

Procyon, a Montreal-based biotechnology company, develops therapeutics in the fields of cancer and HIV/AIDS. In January, Procyon acquired Cellpep, forming a new entity, Ambrilia Biopharma Inc.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.